Industry News
Skin cancer costs 30 times more to treat than prevent
Despite being largely preventable, skin cancer costs Victoria's public hospitals more than $50 million a year, new research from Deakin University and Cancer Council Victoria has found. [ + ]
Fujitsu develops AI technology for CT inspections
Fujitsu Laboratories has developed a technology to retrieve similar disease cases from a computed tomography (CT) database of previously taken images. [ + ]
Studying motor molecules, at the nanoscale
University of Queensland physicists are applying quantum physics to single molecule sensing for the first time, creating the possibility of detecting cancer at its earliest stages. [ + ]
Aus cancer vaccine closer to human trials
Radvax, a cancer treatment vaccine, being developed by South Australian company Vaxine, is closer to human trials. [ + ]
Better managing antibiotic use in sepsis patients
UK researchers are taking part in a £1.5 million study aiming to antibiotic resistance in sepsis patients — the largest ever trial to look at biomarkers in the blood to see whether antibiotics should be continued or can be safely stopped. [ + ]
Innate reveals "distressing" MS trial results
Innate Immunotherapeutics has reluctantly announced that its MS therapy MIS416 showed no meaningful or statistically significant results in a recent Phase 2B trial, with the company's shares dropping a whopping 92% as a result. [ + ]
Monash IVF and RHS begin non-invasive PGS trial
Australian listed companies Monash IVF and RHS (Reproductive Health Science) have partnered to develop an accurate way to test for chromosome number in embryos without biopsy. [ + ]
Miele expands medical tech business with Steelco stake purchase
Miele is set to acquire a controlling stake in the Steelco Group to further expand in the medical technology industry. [ + ]
Prima says IMP321 trial progressing well
Prima BioMed has announced that the company's two active clinical trials in IMP321 are progressing well. [ + ]
Canadian CRO selected to reformulate cancer inhibitor
PharmAust has appointed contract research organisation BRI Pharmaceutical Research Inc to reformulate its lead drug candidate, Monepantel (MPL), for clinical trials. [ + ]
Cancer cells may streamline their genomes to replicate faster
A recent study, conducted in both human and mouse cells, has revealed that cancer cells might streamline their genomes in order to proliferate more easily. [ + ]
LBT Innovations completes CE mark certification for APAS
LBT Innovations and joint venture company Clever Culture Systems AG have completed a comprehensive essential requirements review of the extensive documentation and data packs related to the APAS technology and certify requirements are met for CE Marking. [ + ]
Genome regulation mystery solved
US researchers have addressed a longstanding question about how DNA functions are organised in space and time, including how genes are regulated to be silenced or expressed. [ + ]
New medical cannabis body launched
A new industry body, the Medical Cannabis Council, has been launched with an aim to develop best practice and standards for producing, supplying and distributing medical cannabis. [ + ]
Clinical trials provide $1.1bn to economy
Clinical trials accounted for roughly $1.1 billion in gross expenditure in 2015, and the annual expenditure could reach 2 billion in the next 10 years. [ + ]
